V. Glover

Diagnosis of patients with heart failure with preserved ejection fraction in primary care: cohort study

Jonathan R. Crawshaw, T. Blakeman, C. Chew‐Graham, 2021, ESC Heart Failure.

Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial

F. Markowetz, T. Bray, Shruti Singh, 2020, The Lancet.

Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, feasibility study

M. Gulati, Jennifer A. Williams, S. Dutton, 2022, The Lancet. Rheumatology.

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

Nabil T. Fadai, D. V. Nicolau, P. Barnes, 2021, The Lancet Respiratory Medicine.

Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial

Nabil T. Fadai, D. V. Nicolau, T. Bengtsson, 2021, medRxiv.

Hand Osteoarthritis: investigating Pain Effects of estrogen-containing therapy (HOPE-e): a protocol for a feasibility randomised placebo-controlled trial

S. Lamb, M. Gulati, Jennifer A. Williams, 2021, Pilot and Feasibility Studies.

Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial

F. Markowetz, T. Bray, L. Lovat, 2020, The Lancet.

Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.

I. Binnian, M. Mahdi, H. Jeffers, 2023, The Lancet. Respiratory medicine.